title: Differential biological activity of disease-associated JAK2 mutants.
abstract: The JAK2V617F mutation has been identified in most patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Although JAK2V617F is the predominant allele associated with MPNs, other activating Janus kinase 2 (JAK2) alleles (such as K539L, T875N) also have been identified in distinct MPNs. The basis for the differences in the in vivo effects of different JAK2 alleles remains unclear. We have characterized three different classes of disease-associated JAK2 mutants (JAK2V617F, JAK2K539L and JAK2T875N) and found significant differences in biochemical, signaling and transforming properties among these different classes of JAK2 mutants.
authors.affiliation: Department of Pharmacology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY 13210, USA.
authors.forename: Haiying
authors.initials: H
authors.lastname: Zou
authors.forename: Dongqing
authors.initials: D
authors.lastname: Yan
authors.forename: Golam
authors.initials: G
authors.lastname: Mohi
mesh_terms: D000818:Animals; D002460:Cell Line; D004194:Disease / Q000235:genetics*; D015672:Erythroid Precursor Cells / Q000201:enzymology / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D051379:Mice; D050505:Mutant Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D009154:Mutation; D017434:Protein Structure, Tertiary; D015398:Signal Transduction
chemical_list: D050505:Mutant Proteins; D053614:Janus Kinase 2